{Reference Type}: Journal Article
{Title}: Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies.
{Author}: Nguyen NH;Jarvi NL;Balu-Iyer SV;
{Journal}: J Pharm Sci
{Volume}: 112
{Issue}: 9
{Year}: 2023 09 21
{Factor}: 3.784
{DOI}: 10.1016/j.xphs.2023.05.014
{Abstract}: The introduction and development of biologics such as therapeutic proteins, gene-, and cell-based therapy have revolutionized the scope of treatment for many diseases. However, a significant portion of the patients develop unwanted immune reactions against these novel biological modalities, referred to as immunogenicity, and no longer benefit from the treatments. In the current review, using Hemophilia A (HA) therapy as an example, we will discuss the immunogenicity issue of multiple biological modalities. Currently, the number of therapeutic modalities that are approved or recently explored to treat HA, a hereditary bleeding disorder, is increasing rapidly. These include, but are not limited to, recombinant factor VIII proteins, PEGylated FVIII, FVIII Fc fusion protein, bispecific monoclonal antibodies, gene replacement therapy, gene editing therapy, and cell-based therapy. They offer the patients a broader range of more advanced and effective treatment options, yet immunogenicity remains the most critical complication in the management of this disorder. Recent advances in strategies to manage and mitigate immunogenicity will also be reviewed.